RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
IRLAB Therapeutics Stock

IRLAB Therapeutics P/E 2024

IRLAB Therapeutics P/E

-9

Ticker

IRLAB A.ST

ISIN

SE0012675361

WKN

A2PLBE

As of Oct 6, 2024, IRLAB Therapeutics's P/E ratio was -9, a 270.37% change from the -2.43 P/E ratio recorded in the previous year.

The IRLAB Therapeutics P/E history

IRLAB Therapeutics Aktienanalyse

What does IRLAB Therapeutics do?

IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry. IRLAB Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering IRLAB Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of IRLAB Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing IRLAB Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of IRLAB Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in IRLAB Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about IRLAB Therapeutics stock

What is the price-to-earnings ratio of IRLAB Therapeutics?

The price-earnings ratio of IRLAB Therapeutics is currently -9.

How has the price-earnings ratio of IRLAB Therapeutics changed compared to last year?

The price-to-earnings ratio of IRLAB Therapeutics has increased by 270.37% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of IRLAB Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of IRLAB Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of IRLAB Therapeutics affect the company?

An increase in the price-earnings ratio of IRLAB Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of IRLAB Therapeutics affect the company?

A decrease in the price-earnings ratio of IRLAB Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of IRLAB Therapeutics?

Some factors that influence the price-earnings ratio of IRLAB Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does IRLAB Therapeutics pay?

Over the past 12 months, IRLAB Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IRLAB Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of IRLAB Therapeutics?

The current dividend yield of IRLAB Therapeutics is .

When does IRLAB Therapeutics pay dividends?

IRLAB Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IRLAB Therapeutics?

IRLAB Therapeutics paid dividends every year for the past 0 years.

What is the dividend of IRLAB Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is IRLAB Therapeutics located?

IRLAB Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von IRLAB Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IRLAB Therapeutics from 10/6/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did IRLAB Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of IRLAB Therapeutics in the year 2023?

In the year 2023, IRLAB Therapeutics distributed 0 SEK as dividends.

In which currency does IRLAB Therapeutics pay out the dividend?

The dividends of IRLAB Therapeutics are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von IRLAB Therapeutics

Our stock analysis for IRLAB Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRLAB Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.